• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

DNA错配修复系统通过DNA甲基转移酶调节宫颈癌中PD-L1的表达。

DNA mismatch repair system regulates the expression of PD-L1 through DNMTs in cervical cancer.

作者信息

Guo Fan, Lu Ruijiao, Kong Weina, Anwar Miyessar, Feng Yangchun

机构信息

Department of Medical Laboratory Center, Tumor Hospital Affiliated to Xinjiang Medical University, No 789 Suzhou Road, Urumqi, China.

Postdoctoral Research Workstation of Tumor Hospital affiliated to Xinjiang Medical University, Urumqi, China.

出版信息

Cancer Cell Int. 2024 Jan 10;24(1):25. doi: 10.1186/s12935-024-03214-7.

DOI:10.1186/s12935-024-03214-7
PMID:38200495
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10782574/
Abstract

BACKGROUND

Cervical cancer (CC) is a potential clinical application of PD-1/PD-L1 inhibitor. We aimed to study the mechanism of DNA mismatch repair (MMR) system regulating the expression of PD-L1 in CC through DNA methyltransferase (DNMTs).

METHODS

We collected pathological specimens from 118 cases of CC to analyze the relationship between PD-L1 expression and DNMTs in different MMR states. RNA interference (RNAi) technique was used to simulate the formation of CC cell line with MMR deficiency (dMMR) state, and subcutaneous tumor formation experiment was carried out in nude mice to verify the relationship between PD-L1 expression and DNMTs in MMR state.

RESULTS

The PD-L1 positive rate in 118 cases of CC was 58.47%, while the microsatellite instability (MSI) status accounted for 5.93%. There was a significant difference in the expression of PD-L1 between patients within the dMMR and MMR proficient (pMMR) groups (χ = 21.405, P < 0.001). Subcutaneous inoculation after infection of Siha cells led to successful tumorigenesis in nude mice, accompanied by a significant increase in the level of PD-L1 expression in the mouse tumors, while the expression level of MLH1 and MSH2 protein decreased significantly. We also found that PD-L1 expression was closely related to the expression of DNMTs.

CONCLUSION

PD-L1 is universal expressed on the surface of CC cells, dMMR status enhances the expression of PD-L1 on the surface of CC cells, dMMR states of CC are related to the demethylation status of the PD-L1 gene promoter region.

摘要

背景

宫颈癌(CC)是PD-1/PD-L1抑制剂的潜在临床应用对象。我们旨在研究DNA错配修复(MMR)系统通过DNA甲基转移酶(DNMTs)调节CC中PD-L1表达的机制。

方法

收集118例CC的病理标本,分析不同MMR状态下PD-L1表达与DNMTs之间的关系。采用RNA干扰(RNAi)技术模拟MMR缺陷(dMMR)状态的CC细胞系形成,并在裸鼠中进行皮下肿瘤形成实验,以验证MMR状态下PD-L1表达与DNMTs之间的关系。

结果

118例CC中PD-L1阳性率为58.47%,微卫星不稳定性(MSI)状态占5.93%。dMMR组与MMR proficient(pMMR)组患者之间PD-L1表达存在显著差异(χ=21.405,P<0.001)。Siha细胞感染后皮下接种导致裸鼠成功成瘤,同时小鼠肿瘤中PD-L1表达水平显著升高,而MLH1和MSH2蛋白表达水平显著降低。我们还发现PD-L1表达与DNMTs的表达密切相关。

结论

PD-L1在CC细胞表面普遍表达,dMMR状态增强CC细胞表面PD-L1的表达,CC的dMMR状态与PD-L1基因启动子区域的去甲基化状态有关。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ba8b/10782574/86a272342fab/12935_2024_3214_Fig9_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ba8b/10782574/860d2ac869c7/12935_2024_3214_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ba8b/10782574/f00af904fa38/12935_2024_3214_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ba8b/10782574/850dca6bded3/12935_2024_3214_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ba8b/10782574/4cb20cd4acf4/12935_2024_3214_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ba8b/10782574/ab3ddb69f35d/12935_2024_3214_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ba8b/10782574/7edf96675048/12935_2024_3214_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ba8b/10782574/6fedaf5ace52/12935_2024_3214_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ba8b/10782574/5310a6edf343/12935_2024_3214_Fig8_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ba8b/10782574/86a272342fab/12935_2024_3214_Fig9_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ba8b/10782574/860d2ac869c7/12935_2024_3214_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ba8b/10782574/f00af904fa38/12935_2024_3214_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ba8b/10782574/850dca6bded3/12935_2024_3214_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ba8b/10782574/4cb20cd4acf4/12935_2024_3214_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ba8b/10782574/ab3ddb69f35d/12935_2024_3214_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ba8b/10782574/7edf96675048/12935_2024_3214_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ba8b/10782574/6fedaf5ace52/12935_2024_3214_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ba8b/10782574/5310a6edf343/12935_2024_3214_Fig8_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ba8b/10782574/86a272342fab/12935_2024_3214_Fig9_HTML.jpg

相似文献

1
DNA mismatch repair system regulates the expression of PD-L1 through DNMTs in cervical cancer.DNA错配修复系统通过DNA甲基转移酶调节宫颈癌中PD-L1的表达。
Cancer Cell Int. 2024 Jan 10;24(1):25. doi: 10.1186/s12935-024-03214-7.
2
The relationship between the PD-1/PD-L1 pathway and DNA mismatch repair in cervical cancer and its clinical significance.宫颈癌中PD-1/PD-L1通路与DNA错配修复的关系及其临床意义。
Cancer Manag Res. 2018 Jan 18;10:105-113. doi: 10.2147/CMAR.S152232. eCollection 2018.
3
Expression of Programmed Death Ligand 1 [PD-L1] and Mismatch Repair Status in Squamous Cell Carcinomas of Cervix.子宫颈鳞状细胞癌中程序性死亡配体1 [PD-L1] 的表达及错配修复状态
J Obstet Gynaecol India. 2024 Aug;74(4):319-325. doi: 10.1007/s13224-023-01837-w. Epub 2024 Jan 20.
4
High density of cytotoxic T-lymphocytes is linked to tumoral PD-L1 expression regardless of the mismatch repair status in colorectal cancer.在结直肠癌中,无论错配修复状态如何,高细胞毒性 T 淋巴细胞密度与肿瘤 PD-L1 表达相关。
Acta Oncol. 2021 Sep;60(9):1210-1217. doi: 10.1080/0284186X.2021.1933585. Epub 2021 Jun 5.
5
Endometrial Tumors with MSI-H and dMMR Share a Similar Tumor Immune Microenvironment.微卫星高度不稳定(MSI-H)和错配修复缺陷(dMMR)的子宫内膜肿瘤具有相似的肿瘤免疫微环境。
Onco Targets Ther. 2021 Aug 16;14:4485-4497. doi: 10.2147/OTT.S324641. eCollection 2021.
6
Can evaluation of mismatch repair defect and TILs increase the number of triple-negative breast cancer patients eligible for immunotherapy?错配修复缺陷和肿瘤浸润淋巴细胞的评估能否增加符合免疫治疗条件的三阴性乳腺癌患者数量?
Pathol Res Pract. 2021 Oct;226:153606. doi: 10.1016/j.prp.2021.153606. Epub 2021 Aug 31.
7
Tumor microenvironment classification based on T-cell infiltration and PD-L1 in patients with mismatch repair-proficient and -deficient colorectal cancer.基于错配修复功能正常和缺陷的结直肠癌患者中T细胞浸润和PD-L1的肿瘤微环境分类
Oncol Lett. 2019 Feb;17(2):2335-2343. doi: 10.3892/ol.2018.9826. Epub 2018 Dec 12.
8
Programmed death-ligand 1 expression in gastric cancer: correlation with mismatch repair deficiency and HER2-negative status.程序性死亡配体 1 在胃癌中的表达:与错配修复缺陷和 HER2 阴性状态的相关性。
Cancer Med. 2018 Jun;7(6):2612-2620. doi: 10.1002/cam4.1502. Epub 2018 Apr 19.
9
ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: a systematic review-based approach.ESMO 关于免疫治疗中肿瘤微卫星不稳定性检测的建议,及其与 PD-1/PD-L1 表达和肿瘤突变负担的关系:基于系统评价的方法。
Ann Oncol. 2019 Aug 1;30(8):1232-1243. doi: 10.1093/annonc/mdz116.
10
Mismatch repair-deficient colorectal cancer: a model of immunogenic and immune cell-rich tumor despite nonsignificant programmed cell death ligand-1 expression in tumor cells.错配修复缺陷型结直肠癌:尽管肿瘤细胞中程序性细胞死亡配体 1 的表达无显著意义,但仍是一种免疫原性和免疫细胞丰富的肿瘤模型。
Hum Pathol. 2018 Feb;72:135-143. doi: 10.1016/j.humpath.2017.09.019. Epub 2017 Dec 5.

引用本文的文献

1
Immune-checkpoint inhibition for tumor prevention in a preclinical Lynch syndrome model.在临床前林奇综合征模型中,免疫检查点抑制用于肿瘤预防。
Transl Oncol. 2025 Jul 16;60:102472. doi: 10.1016/j.tranon.2025.102472.
2
Complete remission of a high-risk, locally advanced cervical cancer with para-aortic lymph node metastases treated with first-line tislelizumab plus bevacizumab combined with chemotherapy followed by radiotherapy with maintenance therapy: a case report.一线替雷利珠单抗联合贝伐单抗化疗后放疗并维持治疗,使伴有主动脉旁淋巴结转移的高危局部晚期宫颈癌完全缓解:一例报告
Front Immunol. 2025 May 1;16:1573202. doi: 10.3389/fimmu.2025.1573202. eCollection 2025.

本文引用的文献

1
DNMT1 constrains IFNβ-mediated anti-tumor immunity and PD-L1 expression to reduce the efficacy of radiotherapy and immunotherapy.DNA甲基转移酶1(DNMT1)抑制IFNβ介导的抗肿瘤免疫和PD-L1表达,从而降低放疗和免疫治疗的疗效。
Oncoimmunology. 2021 Oct 21;10(1):1989790. doi: 10.1080/2162402X.2021.1989790. eCollection 2021.
2
Efficacy and Safety of PD-1/PD-L1 Inhibitor as Single-Agent Immunotherapy in Endometrial Cancer: A Systematic Review and Meta-Analysis.PD-1/PD-L1抑制剂作为单药免疫疗法治疗子宫内膜癌的疗效与安全性:一项系统评价和荟萃分析
Cancers (Basel). 2023 Aug 9;15(16):4032. doi: 10.3390/cancers15164032.
3
Strategies to eliminate cervical cancer in China.
中国消除宫颈癌的策略。
Front Oncol. 2023 Jun 2;13:1105468. doi: 10.3389/fonc.2023.1105468. eCollection 2023.
4
Immunotherapy for deficient mismatch repair (dMMR) pancreatic ductal adenocarcinoma.错配修复缺陷(dMMR)胰腺导管腺癌的免疫疗法。
J Gastrointest Oncol. 2023 Apr 29;14(2):1175-1177. doi: 10.21037/jgo-23-12. Epub 2023 Mar 7.
5
Long non-coding RNAs as critical regulators and novel targets in cervical cancer: current status and future perspectives.长非编码 RNA 作为宫颈癌的关键调控因子和新型治疗靶点:现状与展望。
Apoptosis. 2023 Aug;28(7-8):925-942. doi: 10.1007/s10495-023-01840-6. Epub 2023 Apr 25.
6
Targeting DNA polymerase β elicits synthetic lethality with mismatch repair deficiency in acute lymphoblastic leukemia.靶向 DNA 聚合酶 β 可在急性淋巴细胞白血病中引起与错配修复缺陷的合成致死作用。
Leukemia. 2023 Jun;37(6):1204-1215. doi: 10.1038/s41375-023-01902-3. Epub 2023 Apr 24.
7
Trends in Incidence Rates, Mortality Rates, and Age-Period-Cohort Effects of Cervical Cancer - China, 2003-2017.2003 - 2017年中国宫颈癌发病率、死亡率及年龄 - 时期 - 队列效应趋势
China CDC Wkly. 2022 Dec 2;4(48):1070-1076. doi: 10.46234/ccdcw2022.216.
8
Discordance of microsatellite instability and mismatch repair immunochemistry occurs depending on the cancer type.微卫星不稳定性与错配修复免疫化学之间的不一致性会因癌症类型而异。
Hum Pathol. 2023 May;135:54-64. doi: 10.1016/j.humpath.2022.12.016. Epub 2022 Dec 31.
9
Intraindividual Tumor Heterogeneity of Mismatch Repair Status in Metastatic Colorectal Cancer.转移性结直肠癌中错配修复状态的个体内肿瘤异质性。
Appl Immunohistochem Mol Morphol. 2023 Feb 1;31(2):84-93. doi: 10.1097/PAI.0000000000001089. Epub 2022 Nov 22.
10
Current progress and future perspectives of neoadjuvant anti-PD-1/PD-L1 therapy for colorectal cancer.新辅助抗 PD-1/PD-L1 治疗结直肠癌的现状与展望。
Front Immunol. 2022 Sep 9;13:1001444. doi: 10.3389/fimmu.2022.1001444. eCollection 2022.